As the U.S. stock market navigates through a period of heightened volatility with the S&P 500 and Nasdaq Composite recently hitting record highs, investors are closely monitoring developments around tariffs and political shifts that could impact economic conditions. In this dynamic environment, identifying high-growth tech stocks requires careful consideration of their resilience to market fluctuations and adaptability to evolving global trade policies.
Top 10 High Growth Tech Companies In The United States
| Name | Revenue Growth | Earnings Growth | Growth Rating |
|---|---|---|---|
| Super Micro Computer | 24.71% | 39.09% | ★★★★★★ |
| Circle Internet Group | 32.27% | 61.44% | ★★★★★★ |
| Ardelyx | 21.05% | 61.75% | ★★★★★★ |
| Mereo BioPharma Group | 50.84% | 58.22% | ★★★★★★ |
| TG Therapeutics | 26.46% | 38.75% | ★★★★★★ |
| AVITA Medical | 27.42% | 61.04% | ★★★★★★ |
| Alkami Technology | 20.53% | 76.67% | ★★★★★★ |
| Alnylam Pharmaceuticals | 23.72% | 59.95% | ★★★★★★ |
| Ascendis Pharma | 35.07% | 59.92% | ★★★★★★ |
| Lumentum Holdings | 23.02% | 103.97% | ★★★★★★ |
Click here to see the full list of 224 stocks from our US High Growth Tech and AI Stocks screener.
We'll examine a selection from our screener results.
Zai Lab (ZLAB)
Simply Wall St Growth Rating: ★★★★★☆
Overview: Zai Lab Limited is a biopharmaceutical company dedicated to the discovery, development, and commercialization of treatments for oncology, immunology, neuroscience, and infectious diseases with a market cap of approximately $4.03 billion.
Operations: Zai Lab generates revenue primarily from its biotechnology segment, which accounts for $418.33 million. The company's focus spans oncology, immunology, neuroscience, and infectious diseases.
Zai Lab's strategic focus on innovative cancer treatments is underscored by its recent success in the Phase 3 FORTITUDE-101 trial, which significantly improved survival rates for gastric cancer patients. This achievement not only highlights Zai Lab's commitment to addressing unmet medical needs but also positions it favorably in the biotech industry, where rapid advancements are critical. Despite its current unprofitability, Zai Lab is expected to see a revenue increase of 30.4% annually, outpacing the US market projection of 8.7%. Additionally, with an anticipated profit growth rate of 66.47% per year and ongoing investments in groundbreaking research like their bispecific antibody ZL-1503 for atopic dermatitis, Zai Lab demonstrates a robust potential for future growth and innovation in high-stakes medical fields.
- Get an in-depth perspective on Zai Lab's performance by reading our health report here.
Gain insights into Zai Lab's past trends and performance with our Past report.
Apellis Pharmaceuticals (APLS)
Simply Wall St Growth Rating: ★★★★★☆
Overview: Apellis Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company dedicated to discovering, developing, and commercializing novel therapeutic compounds for diseases with high unmet needs, with a market cap of approximately $2.29 billion.
Operations: Apellis focuses on developing and commercializing novel therapeutics, generating approximately $775.84 million in revenue from this segment.
Apellis Pharmaceuticals, despite its current unprofitability, is poised for significant growth with an anticipated 16% annual revenue increase and a forecasted profit surge of 64% per year. This growth trajectory surpasses the broader US market's projections of 8.7% revenue growth. The recent VALIANT study results further underscore Apellis's potential, demonstrating EMPAVELI’s effectiveness in treating kidney-related diseases with a notable 68% reduction in proteinuria at Week 26, sustained over a year. These developments not only highlight Apellis's commitment to innovative healthcare solutions but also position it as a promising entity in the biopharmaceutical sector with robust future prospects.
BridgeBio Pharma (BBIO)
Simply Wall St Growth Rating: ★★★★★☆
Overview: BridgeBio Pharma, Inc. is a commercial-stage biopharmaceutical company focused on discovering, developing, and delivering transformative medicines for genetic diseases and cancers, with a market cap of $8.35 billion.
Operations: BridgeBio Pharma focuses on creating and delivering transformative medicines for genetic diseases and cancers, generating revenue of $127.42 million from its efforts in identifying and advancing these treatments.
Despite recent setbacks, including being dropped from multiple Russell indexes, BridgeBio Pharma remains a compelling narrative within the biopharmaceutical sector. With an impressive annual revenue growth forecast at 41.5% and expected earnings growth of 64.35%, the company is strategically positioning itself for profitability within three years. Notably, its R&D commitment is robust, underpinning innovations like acoramidis—a near-complete transthyretin stabilizer showing promising clinical outcomes in cardiomyopathy treatment. These developments suggest that while challenges persist, BridgeBio's focus on groundbreaking treatments could significantly impact patient care and its market position in upcoming years.
- Dive into the specifics of BridgeBio Pharma here with our thorough health report.
Examine BridgeBio Pharma's past performance report to understand how it has performed in the past.
Make It Happen
- Dive into all 224 of the US High Growth Tech and AI Stocks we have identified here.
- Are you invested in these stocks already? Keep abreast of every twist and turn by setting up a portfolio with Simply Wall St, where we make it simple for investors like you to stay informed and proactive.
- Join a community of smart investors by using Simply Wall St. It's free and delivers expert-level analysis on worldwide markets.
Contemplating Other Strategies?
- Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
- Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
- Find companies with promising cash flow potential yet trading below their fair value.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Valuation is complex, but we're here to simplify it.
Discover if BridgeBio Pharma might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com